PANIC DISORDER · White paper
Panic Disorder Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About panic disorder — and why its trials are hard
Panic disorder is an anxiety disorder defined by recurrent, unexpected panic attacks, sudden surges of intense fear peaking within minutes, followed by persistent anticipatory anxiety and maladaptive avoidance. It affects roughly 2.7% of U.S. adults annually (lifetime prevalence about 4.7%), is about twice as common in women, and typically emerges in late adolescence or early adulthood (mean onset around age 24). It is coded 6B01 in ICD-11. Pathophysiology implicates serotonergic and noradrenergic dysregulation and heightened fear-circuit reactivity (amygdala, prefrontal cortex). Evidence-based treatment combines pharmacotherapy and psychotherapy: SSRIs (sertraline, paroxetine, fluoxetine) and the SNRI venlafaxine are first-line for maintenance, while benzodiazepines (alprazolam, clonazepam) give rapid acute relief but carry dependence risk and are reserved for short-term use. Cognitive behavioral therapy is the gold-standard psychotherapy. Trials commonly measure panic-attack frequency and the proportion of patients becoming panic-free. Key methodological challenges include very high placebo response rates, publication bias that has overstated some agents' efficacy, patient heterogeneity, and safety issues that have derailed candidates such as nefazodone.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Sertraline (Zoloft) | 1996 | First-line maintenance pharmacotherapy for panic disorder (SSRI; PD indication approved 1996, drug first approved 1991) | Studies PD-1 & PD-2 (10-week) | Reduction in panic-attack frequency; CGI-S/CGI-I | About 2 fewer full panic attacks per week vs placebo; significant CGI improvement and lower relapse in continuation |
| Paroxetine (Paxil) | 1996 | First-line maintenance pharmacotherapy for panic disorder (SSRI) | Fixed-dose Study 1 (10-week) | Proportion of patients free of panic attacks | 76% panic-attack-free at 40 mg/day vs 44% on placebo; significantly reduced relapse in continuation |
| Fluoxetine (Prozac) | 1994 | Maintenance pharmacotherapy for panic disorder (SSRI) | Flexible-dose Studies 1 & 2 (12-week) | Proportion of patients free of panic attacks at endpoint | 42% (Study 1) and 62% (Study 2) panic-free vs 28% and 44% on placebo |
| Venlafaxine ER (Effexor XR) | 2005 | Panic disorder, including with comorbid anxiety (SNRI) | Studies 1 & 2 (12-week) | Proportion free of full-symptom panic attacks | 54-70% free of full-symptom attacks vs 34-47% placebo (odds ratios ~2.3-3.0); reduced relapse |
| Alprazolam (Xanax) | 1981 | Short-term relief of acute panic symptoms (benzodiazepine; PD indication established, drug approved 1981) | Pooled controlled studies (up to 10 weeks) | Number of patients achieving zero panic attacks; global improvement | 37-83% achieved zero panic attacks; superior to placebo, though dependence limits long-term use |
| Clonazepam (Klonopin) | 1997 | Short-term control of panic attacks (benzodiazepine) | Fixed- and flexible-dose studies (6-9 weeks) | Proportion free of full panic attacks; CGI | 62-74% free of full panic attacks vs 37-56% placebo; ~1 fewer attack/week |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in panic disorder development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Nefazodone — Panic disorder development program | Development for panic disorder discontinued in 2004; drug later withdrawn | Hepatotoxicity concerns led to market withdrawal, emphasizing the primacy of safety in anxiolytic development |
| CI-988 (CCK-B receptor antagonist) — Panic disorder studies | Failed to show efficacy in humans | Minimal therapeutic effect despite promising preclinical data, exposing poor animal-to-human translation |
| Darigabat (GABA-A PAM) — GABA-A modulator program | Discontinued for generalized anxiety disorder for lack of efficacy; panic-disorder work not established | Lack of efficacy in a related anxiety indication highlighted the difficulty of novel GABAergic mechanisms (unverified for panic disorder specifically) |
Choosing the right endpoint
Primary endpoints that matter in panic disorder trials
- Reduction in panic-attack frequency — Core efficacy measure; complicated by variability in attack triggers and patient recording
- Proportion panic-attack-free (response/remission) — Common categorical endpoint (e.g., patients with zero or <=1 attacks) used across SSRI/SNRI approvals
- Clinical Global Impression (CGI-S / CGI-I) — Clinician-rated severity and improvement; standard supportive endpoint in psychiatric trials
- Panic Disorder Severity Scale (PDSS) / PAAS — Validated multidimensional severity scales capturing frequency, distress and impairment
- Functional impairment and relapse prevention — Assessed in continuation/randomized-withdrawal phases to demonstrate durability of benefit
How iNGENū runs panic disorder trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Panic Disorder clinical trials — FAQs
What are the first-line medications for panic disorder?
What endpoints define success in panic disorder trials?
Why do panic disorder trials often struggle?
Ready to discuss your panic disorder trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal